<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id>
    <journal-id journal-id-type="publisher-id">pr</journal-id>
    <journal-id journal-id-type="coden">jprobs</journal-id>
    <journal-title-group>
      <journal-title>Journal of Proteome Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-3893</issn>
    <issn pub-type="epub">1535-3907</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9904288</article-id>
    <article-id pub-id-type="pmid">36507870</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jproteome.2c00512</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CPPA: A Web Tool
for Exploring Proteomic and Phosphoproteomic
Data in Cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Hu</surname>
          <given-names>Guo-sheng</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="notes4" ref-type="notes">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Zheng</surname>
          <given-names>Zao-zao</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="notes4" ref-type="notes">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>He</surname>
          <given-names>Yao-hui</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="notes4" ref-type="notes">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Wang</surname>
          <given-names>Du-chuang</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="notes4" ref-type="notes">§</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath5">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3434-4162</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Wen</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <aff id="aff1"><label>†</label>State
Key Laboratory of Cellular Stress Biology, School of Life Sciences,
Faculty of Medicine and Life Sciences, <institution>Xiamen
University</institution>, Xiang’an South Road, Xiamen, Fujian 361102, <country>China</country></aff>
      <aff id="aff2"><label>‡</label>Fujian
Provincial Key Laboratory of Innovative Drug Target Research, School
of Pharmaceutical Sciences, Faculty of Medicine and Life Sciences, <institution>Xiamen University</institution>, Xiang’an South Road, Xiamen, Fujian 361102, <country>China</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>w2liu@xmu.edu.cn</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>03</day>
      <month>02</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>22</volume>
    <issue>2</issue>
    <issue-title>Software Tools and Resources
2023</issue-title>
    <fpage>368</fpage>
    <lpage>373</lpage>
    <history>
      <date date-type="received">
        <day>24</day>
        <month>08</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr2c00512_0003" id="ab-tgr1"/>
      </p>
      <p>A tremendous amount
of proteomic and phosphoproteomic data has
been produced over the years with the development of mass spectrometry
techniques, providing us with new opportunities to explore and understand
the proteome and phosphoproteome as well as the function of proteins
and protein phosphorylation sites. However, a lack of powerful tools
that we can utilize to explore these valuable data limits our understanding
of the proteome and phosphoproteome, particularly in diseases such
as cancer. To address these unmet needs, we established CPPA (Cancer
Proteome and Phosphoproteome Atlas), a web tool to mine abnormalities
of the proteome and phosphoproteome in cancer based on published data
sets. All analysis results are presented in CPPA with a flexible web
interface to provide key customization utilities, including general
analysis, differential expression profiling, statistical analysis
of protein phosphorylation sites, correlation analysis, similarity
analysis, survival analysis, pathological stage analysis, etc. CPPA
greatly facilitates the process of data mining and therapeutic target
discovery by providing a comprehensive analysis of proteomic and phosphoproteomic
data in normal and tumor tissues with a simple click, which helps
to unlock the precious value of mass spectrometry data by bridging
the gap between raw data and experimental biologists. CPPA is currently
available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cppa.site/cppa">https://cppa.site/cppa</uri>.</p>
    </abstract>
    <kwd-group>
      <kwd>proteome</kwd>
      <kwd>phosphoproteome</kwd>
      <kwd>cancer</kwd>
      <kwd>web tool</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>31871319</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Fujian Province of China</institution>
            <institution-id institution-id-type="doi">NA</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2020J02004</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Central University Basic Research Fund of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100018594</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>20720220003</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Central University Basic Research Fund of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100018594</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>20720190145</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>China Postdoctoral Science Foundation</institution>
            <institution-id institution-id-type="doi">10.13039/501100002858</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022M720119</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministry of Science and Technology of the People''s Republic of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100002855</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2020YFA0803600</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Ministry of Science and Technology of the People''s Republic of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100002855</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2020YFA0112300</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>91953114</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>82125028</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>81861130370</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>81761128015</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>pr2c00512</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>pr2c00512</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Large-scale
omics data resources, such as the International Cancer
Genome Consortium (ICGC)<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and the Cancer
Genome Atlas (TCGA),<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> have greatly helped
us understand the characteristics of a wide variety of cancers. Through
these data resources, molecular aberrations at DNA, RNA, and epigenetic
levels can be systematically identified for screening novel biomarkers
or candidate drug targets.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> The study of genomics
and transcriptomics is the first step toward precision oncology, and
proteomics has, in many quarters, been considered the next logical
step in expanding our understanding of tumor biology because it provides
information that complements genomic and transcriptomic data.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Clinical Proteomic Tumor Analysis Consortium
(CPTAC) is a project that aims to accelerate the understanding of
the molecular basis of cancer through the application of large-scale
proteome and genome analysis.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> CPTAC has
so far produced proteomic and phosphoproteomic data across 15 different
types of tumors, covering over 2000 patients. However, the statistical
analysis and data visualization provided by the data portal of CPTAC
are not convenient enough for researchers with limited bioinformatics
skills, thus limiting the potential values of CPTAC data sets. Therefore,
it is important to develop user-friendly tools to analyze and visualize
the data sets in CPTAC. A key step toward understanding cancer is
to analyze the changes of proteins as well as post-translational modifications
(PTMs) such as phosphorylation in tumor tissues through proteomic
and phosphoproteomic data. The differential expression of proteins
between normal and tumor tissues is generally analyzed through statistical
methods.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Many potential biomarkers and
therapeutic targets have been identified based on abnormally expressed
proteins in a variety of cancers, including esophageal cancer,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> breast cancer,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> colorectal
cancer,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> liver cancer,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and so on. Besides the changes in abundance, proteins generate
tremendous diversity, complexity, and heterogeneity through PTMs.
There are currently over 300 different types of PTMs, but only a few
have been studied in depth,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> including
phosphorylation, methylation, acetylation, ubiquitin, glycosylation,
etc. How to systematically and comprehensively study these PTMs is
one of the main challenges in proteomics research. Protein phosphorylation,
principally on serine, threonine, or tyrosine residues, is one of
the most important and well-studied post-translational modifications.
Protein phosphorylation plays a critical role in both physiological
and pathological conditions.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Therefore,
proteomic and phosphoproteomic data may provide precious insights
into tumor biology that cannot be deciphered by genomic analysis.</p>
    <p>Currently, there are many excellent web tools for statistical analysis
and data visualization of cancer genomic and transcriptomic data,
including cBioPortal,<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> GEPIA,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> UALCAN,<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> and so on. cBioPortal
is focused on tumor samples and provides an interface for cancer genomic
data download and visualization. GEPIA provides interactive analysis
of transcriptome data from TCGA and GTEx.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> UALCAN provides multiform data analysis by using transcriptomic
data well as pan-cancer expression analysis based on proteomic data.
In addition, HPA provides an atlas analysis of tissue, blood, cells,
and organs based on proteomic, transcriptomic, and system biology
data resources.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> HPA can also provide
protein abundance analysis according to immunohistochemistry, but
is limited to tumor tissues. LinkedOmics provides interactive analysis
across 10 cancer types based on proteomic and phosphoproteomic data,
but the operating logic is complex and must specify one gene as the
core in the analysis.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> Taken together,
none of the tools can take full advantage of the proteomic and phosphoproteomic
data from CPTAC or other published data sets for systematic statistical
analysis and visual exhibition of proteins and phosphorylation sites
in both normal and cancer samples. To address these unmet needs, we
developed CPPA (Cancer Proteome and Phosphoproteome Atlas), a comprehensive
web tool to identify aberrant patterns of proteins and phosphorylation
sites that are correlated to clinical records in cancer.</p>
  </sec>
  <sec id="sec2">
    <title>Methods and Results</title>
    <sec id="sec2.1">
      <title>Data Collection</title>
      <p>The data sets included in CPPA were
collected from published data sets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_001.xlsx">Table S1</ext-link>), most of which were downloaded from CPTAC, which encompasses mass
spectrometry (MS)-based proteomic data, phosphoproteomic data, and
clinical records from over 2000 cancer patients. The operation processes
of the proteome and phosphoproteome based on mass spectrometry are
complex, and the quality of data generated by different institutions
or laboratories could be largely different. Considering the current
situation of proteomic data and the intention of the website design
herein, five criteria were applied for screening the data sets. First,
proteomic data should be labeled with isobaric tandem mass tags, such
as isobaric tags for relative and absolute quantification reagents
(iTRAQ) and tandem mass tag (TMT) reagents, which improve the data
quality and reproducibility. Second, phosphoproteomic data must be
produced together with the proteomic data using the same batch of
samples. Third, tumor tissues must be collected before the patients
are treated. Fourth, normal samples must be produced in the same project
based on the predesigned prototype of this database. Fifth, the number
of samples must be greater than 50. The final data sets included in
CPPA contained 13 different types of cancer samples, covering nearly
1500 patients.</p>
    </sec>
    <sec id="sec2.2">
      <title>Data Preprocessing</title>
      <p>Proteomic and
phosphoproteomic raw
data were downloaded from the CPTAC data portal or PRIDE (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/pride/">https://www.ebi.ac.uk/pride/</uri>). All proteomic and phosphoproteomic raw data from different sources
have been recomputed through a standard pipeline to minimize the abiologic
difference.</p>
      <p>MaxQuant software (version 2.0.2.0) was used to
analyze MS raw files.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> MS/MS spectra were
searched against the reviewed SwissProt human proteome database and
a common contaminants database by the Andromeda search engine.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> If the “internal reference”, such
as a mixed sample, exists, the reference channel will be set according
to the corresponding plex, and the normalization method will be set
as “Weighted ratio to reference channel”.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Carbamidomethylation was applied as fixed and
N-terminal acetylation, deamidation at NQ, and methionine oxidation
as variable modifications. Phosphorylation of serine, threonine, and
tyrosine (S, T, and Y) was set as variable modifications in analysis
pipeline of phosphoproteomic raw data. Enzyme specificity was set
to “Trypsin/P” or “Trypsin/P + LysC” with
a maximum of 2 missed cleavages and a minimum peptide length of 7
amino acids according to corresponding published papers. A false discovery
rate (FDR) of 1% was applied at the peptide and protein level. Peptide
identification was performed with an allowed initial precursor mass
deviation of up to 7 ppm and an allowed fragment mass deviation of
20 ppm. Protein identification required at least 1 “razor +
unique peptides”. Data were filtered for common contaminants
in proteomic data and phosphoproteomic data, and protein groups only
identified by peptides with modifications were excluded from further
analysis in proteomic data.</p>
      <p>Standard pipeline analysis of proteomic
raw data consumed approximately
100 000 h of CPU time, while the phosphoproteomics analysis
pipeline took nearly 600 000 h of CPU time to run out.</p>
      <p>To mitigate systematic and sample-specific bias in the quantification,
the expression ratios were log<sub>2</sub>-transformed and normalized
using the median centering method across proteins and phosphorylation
sites.</p>
      <p>Finally, we generated a structured table containing the
information
about the number of samples and identified proteins and phosphorylation
sites in each data set (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_001.xlsx">Table S1</ext-link>).</p>
      <p>Clinical information was downloaded from the CPTAC data portal
or obtained from published papers. Major clinical parameters, including
clinical stage, pathological stage, histological grade, age, gender,
survival time, and vital status of all cancer patients, were further
organized into structured data tables.</p>
    </sec>
    <sec id="sec2.3">
      <title>Implementations</title>
      <p>The web tool was hosted by Nginx in
ubuntu 20.04. The back end was implemented using Flask v2.0.2. All
processed data described above were imported and stored into SQLite
relational database. The front end was built using HTML, CSS, and
JavaScript, including the Bootstrap framework (v4) for the styling
and jQuery for HTML scripts. Statistical results are generated by
Python or R. Analysis results in CPPA were exhibited by tables or
plots. Tables are created by Bootstrap Table (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bootstrap-table.com/">https://bootstrap-table.com/</uri>) and plots are generated by plotly.js library (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plot.ly/">https://plot.ly/</uri>) or R package ggplot2.
Survival analysis is generated by R package survminer (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Schema describing data
processing and data display for the CPPA
web tool.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr2c00512_0001" id="gr1" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.4">
      <title>Functionalities</title>
      <p>Functionalities of CPPA are divided
into multiple major modules: General analysis, Differential profile,
Protein phosphorylation analysis, Custom expression analysis, Correlation
analysis, Similarity analysis, and Survival analysis (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The “Help”
webpage, provided by CPPA website, describes the full analysis tutorial
and detailed user manual (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cppa.site/cppa/tppa_help">https://cppa.site/cppa/tppa_help</uri>).</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Examples of CPPA interactive
results. (A) Users can query abundance
of proteins (upper panel) and distribution of phosphorylation sites
(bottom panel) by “General” module. (B) Differential
expression analysis is displayed by pie chart (upper panel, left)
and volcano plot (upper panel, right) in CPPA. The normalized expression
level, fold change, and <italic>Q</italic> value is shown in a table
(bottom panel). (C) Distribution (upper panel) and abundance of phosphorylation
sites (bottom panel) in proteins are displayed through lollipop plot
and heat map, respectively. (D) Customized expression analysis (left
panel), pathological stage analysis (right panel, upper), and comparison
analysis (right panel, bottom) are exhibited through box plot, violin
plot, and heat map, respectively. (E) CPPA provides correlation analysis
of pairwise proteins or phosphorylation sites, and query interface
of similar expression pattern through “Correlation and similarity
analysis” function. (F) CPPA provides survival analysis and
query results about survival relevant proteins and phosphorylation
sites.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr2c00512_0002" id="gr2" position="float"/>
      </fig>
      <sec id="sec2.4.1">
        <title>General Analysis</title>
        <p>Index of CPPA provides
a simple query
interface that takes Gene Symbol (e.g., SF3B1), UniProt ID (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="UniProt" xlink:href="O75533">O75533</ext-link>), or Ensembl
ID (e.g., ENSG00000115524) as input. After entering an identifier
and clicking the “Search!” button, the website will
navigate to pan-cancer analysis webpage, which presents the protein
expression profile by box plot or violin plot and the distribution
of phosphorylation sites through lollipop plot across all cancer types
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). In addition,
this module also provides basic information about proteins and external
websites linking to this protein, including UniProt, GeneCard, PhosphoSitePlus,
HPA, and so on.</p>
      </sec>
      <sec id="sec2.4.2">
        <title>Differential Profile</title>
        <p>Dysregulation
of protein expression
or protein phosphorylation is one of the major causes of occurrence
and development of cancer.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Identifying
differentially expression profiles between normal and tumor tissues
is very helpful for inferring cancer driver factors, seeking specific
biomarkers, and screening potential anticancer drug targets.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> CPPA provides an interface for exhibiting differential
abundance profiles for proteins and protein phosphorylation. The significance
of differences was calculated between normal and tumor samples by
using the Wilcoxon signed-rank test, and then the Benjamini–Hochberg
tutorial was applied to correct the <italic>P</italic>-values for
better accuracy. This module allows users to obtain the differential
expression profiles of tens of thousands of proteins and protein phosphorylation
sites in normal and tumor samples according to user-specified <italic>P</italic>-value and fold change cutoffs (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B). For proteomic data, CPPA also provides
functional enrichment analysis based on MsigDB aggregated gene sets,
such as Hallmark, GO, KEGG, Reactome, WikiPathway, among others (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_002.pdf">Figure S1A</ext-link>). In addition, kinase-substrate enrichment
analysis is added to CPPA for exploring kinase activity in cancer
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_002.pdf">Figure S1B</ext-link>).</p>
      </sec>
      <sec id="sec2.4.3">
        <title>Protein Phosphorylation
Analysis</title>
        <p>A protein can have
multiple phosphorylation sites, which are likely to be different in
abundance and molecular function. For example, depending on the sites
involved, phosphorylation of the Elk-1 TAD by a single kinase, ERK,
can either promote or inhibit mediator interaction, thereby modulating
transcriptional activation.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> CPPA provides
an interface that allows users to query all phosphorylation sites
of a specific protein in a particular cancer type. The lollipop plot
exhibits the distribution of phosphorylation sites on the protein,
and the number of tissue samples in which these sites were identified.
The heat map shows log<sub>2</sub>-transformed median abundance of
phosphorylation sites across all normal and tumor tissues (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C). CPPA integrates
relationships between kinases and substrates from PhosphoSitePlus
and NetworKIN to inform users about potential kinases of the phosphorylation
site (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_002.pdf">Figure S1C</ext-link>). In addition, CPPA also
uses linear motif algorithm to predict kinases base on amino acid
sequence surrounding the phosphorylation site through Persues (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_002.pdf">Figure S1D</ext-link>).</p>
      </sec>
      <sec id="sec2.4.4">
        <title>Custom Expression Analysis</title>
        <p>CPPA provides a module to
dynamically generate the abundance profile of a given protein or protein
phosphorylation sites based on user-defined cancer type. The results
are visualized by box plot along with text summarizing the detailed
statistical results and the number of samples. In addition, CPPA also
provides an interface for mapping expression abundance with pathological
stage based on structured patient clinical annotations. Furthermore,
comparison of different proteins or phosphorylation sites across multiple
cancer types can be done in CPPA website, and the analysis results
will be shown by heat map (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D).</p>
      </sec>
      <sec id="sec2.4.5">
        <title>Correlation and Similarity Analysis</title>
        <p>CPPA provides a
module for correlation analysis of paired proteins or phosphorylation
sites, and results are shown by scatter plot. Users are free to choose
the algorithms used to calculate the correlation, such as the Pearson,
Spearman, and Kendall correlation analysis. Moreover, queries for
similar expression pattern of proteins or phosphorylation sites are
integrated into an interface with the same webpage structure. One
of the applications is to seek for proteins or phosphorylation sites
which are highly or inverse correlated with targets of interest in
terms of abundance (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>E).</p>
      </sec>
      <sec id="sec2.4.6">
        <title>Survival Analysis</title>
        <p>CPPA can provide
the survival curves
of user-specified protein or phosphorylation site in a given cancer
type, in which the Kaplan–Meier (KM) model is used to calculate
the survival probability along with death event and survival time.
Users can choose different stratification methods, such as Median,
Tertiles, Quartile, and Best-cutoff, to classify samples into either
high or low expression groups according to abundance. This module
also calculates <italic>P</italic>-value through log-rank test and
hazard ratio by cox proportional regression analysis. Besides, users
can also choose whether or not to display the 95% confidence interval
in survival curves. Similar to correlation analysis, CPPA also provides
an interface for screening proteins or phosphorylation sites that
are highly or inverse correlated with patient survival status in a
given cancer type. The rank of correlation is sorted according to <italic>P</italic>-value and hazard ratio (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>F).</p>
      </sec>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Conclusion and Discussion</title>
    <p>CPPA is a comprehensive and interactive web tool for mining characteristics
of protein and protein phosphorylation sites from nearly 1500 patients
spanning 13 different types of cancers, making use of proteomic and
phosphoproteomic data from published data sets, particularly those
from CPTAC. In order to increase reproducibility of the analysis results,
CPPA standardizes the analysis pipeline through MaxQuant to reduce
nonbiological variations. CPPA provides a variety of analysis results
through multiple predesigned interactive web modules, including differential
expression analysis, protein phosphorylation analysis, expression
abundance analysis, correlation analysis, survival analysis, etc.
Analysis results include approximately 17 000 proteins and
more than 250 000 phosphorylation sites, covering the majority
of the human proteome and phosphoproteome. Through interactive web
operation, experimental biologists with basic bioinformatics skills
can click a button to retrieve a series of analysis results and obtain
images and tables for publication.</p>
    <p>Because of the limitation
of available large-scale high-resolution
mass spectrometry-based data, proteomic and phosphoproteomic data
collected by CPPA only covered 13 cancer types. With the development
of cancer biology, CPPA will continuously collect more proteomic and
phosphoproteomic data from other cancer types and be updated accordingly.
Furthermore, PTMs is an important way to increase the functional diversity
of proteins. In addition to phosphorylation, methylation, glycosylation,
ubiquitination, acetylation, succinylation, other PTM types can almost
affect all aspects of protein function, promoting or suppressing cancer
development. We envision that CPPA can analyze more types of protein
modifications with the development of various PTM omics, providing
further insights into our understanding of cancer.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes1">
    <title>Data Availability Statement</title>
    <p>Cancer
Proteome
and Phosphorylation Atlas (CPPA) analysis platform is available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cppa.site/cppa">https://cppa.site/cppa</uri>. This web
tool is free and open to all users and there is no login requirement.
The “Help” webpage of CPPA includes step-by-step instructions.</p>
  </notes>
  <notes id="notes2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jproteome.2c00512?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.2c00512</ext-link>.<list id="silist" list-type="simple"><list-item><p>Table S1: Description
of data sets contained in CPPA
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Figure
S1: Examples of CPPA interactive results (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.2c00512/suppl_file/pr2c00512_si_002.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr2c00512_si_001.xlsx">
        <caption>
          <p>pr2c00512_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr2c00512_si_002.pdf">
        <caption>
          <p>pr2c00512_si_002.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p>W.L. and G.H.
conceived the original ideas, designed the project, and wrote the
manuscript. G.H. built the system’s back end. G.H. and Z.Z.
designed the web interface. G.H. and Y.H. standardized the analysis
pipeline of proteomic and phosphoproteomic raw data and constructed
the SQLite data sets. D.W. tested and provided critical comments for
the websites.</p>
  </notes>
  <notes notes-type="" id="notes4">
    <title>Author Contributions</title>
    <p><sup>§</sup> G.H., Z.Z.,
Y.H., and D.W. contributed equally.</p>
  </notes>
  <notes notes-type="COI-statement" id="notes5">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work was supported by the Ministry
of Science
and Technology of China (2020YFA0112300, 2020YFA0803600), National
Natural Science Foundation of China (82125028, 91953114, 31871319,
81761128015, and 81861130370), Natural Science Foundation of Fujian
Province of China (2020J02004), and the Fundamental Research Funds
for the Central University (20720190145 and 20720220003) to W. Liu.
This
work was also supported by the China Postdoctoral Science Foundation
(2022M720119) to Zao-zao Zheng. We thank all other members from Liu’s
lab for providing critical comments.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><article-title>International network of cancer genome projects</article-title>. <source>Nature</source><year>2010</year>, <volume>464</volume>, <fpage>993</fpage>–<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1038/nature08987</pub-id>.<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Weinstein</surname><given-names>J. N.</given-names></name>; et al. <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>, <volume>45</volume>, <fpage>1113</fpage>–<lpage>1120</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Yao</surname><given-names>J.</given-names></name>; et al. <article-title>Tumor subtype-specific cancer-testis antigens as potential biomarkers
and immunotherapeutic targets for cancers</article-title>. <source>Cancer
Immunol Res.</source><year>2014</year>, <volume>2</volume>, <fpage>371</fpage>–<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0088</pub-id>.<pub-id pub-id-type="pmid">24764584</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><article-title>Comprehensive molecular characterization of urothelial
bladder carcinoma</article-title>. <source>Nature</source><year>2014</year>, <volume>507</volume>, <fpage>315</fpage>–<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1038/nature12965</pub-id>.<pub-id pub-id-type="pmid">24476821</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Pennington</surname><given-names>S. R.</given-names></name><article-title>Revolutionizing
Precision Oncology through Collaborative
Proteogenomics and Data Sharing</article-title>. <source>Cell</source><year>2018</year>, <volume>173</volume>, <fpage>535</fpage>–<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.04.008</pub-id>.<pub-id pub-id-type="pmid">29677503</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Edwards</surname><given-names>N. J.</given-names></name>; et al. <article-title>The CPTAC Data Portal:
A Resource for Cancer Proteomics Research</article-title>. <source>J.
Proteome Res.</source><year>2015</year>, <volume>14</volume>, <fpage>2707</fpage>–<lpage>2713</lpage>. <pub-id pub-id-type="doi">10.1021/pr501254j</pub-id>.<pub-id pub-id-type="pmid">25873244</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Lin</surname><given-names>M. H.</given-names></name>; et al. <article-title>Benchmarking differential
expression, imputation and quantification
methods for proteomics data</article-title>. <source>Brief Bioinform</source><year>2022</year>, <pub-id pub-id-type="doi">10.1093/bib/bbac138</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Liu</surname><given-names>W.</given-names></name>; et al. <article-title>Large-scale and high-resolution
mass spectrometry-based proteomics
profiling defines molecular subtypes of esophageal cancer for therapeutic
targeting</article-title>. <source>Nat. Commun.</source><year>2021</year>, <volume>12</volume>, <fpage>4961</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25202-5</pub-id>.<pub-id pub-id-type="pmid">34400640</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Krug</surname><given-names>K.</given-names></name>; et al. <article-title>Proteogenomic Landscape of Breast Cancer Tumorigenesis
and Targeted
Therapy</article-title>. <source>Cell</source><year>2020</year>, <volume>183</volume>, <fpage>1436</fpage>–<lpage>1456</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.036</pub-id>.<pub-id pub-id-type="pmid">33212010</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Vasaikar</surname><given-names>S.</given-names></name>; et al. <article-title>Proteogenomic Analysis
of Human Colon Cancer Reveals New Therapeutic
Opportunities</article-title>. <source>Cell</source><year>2019</year>, <volume>177</volume>, <fpage>1035</fpage>–<lpage>1049</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.03.030</pub-id>.<pub-id pub-id-type="pmid">31031003</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Gao</surname><given-names>Q.</given-names></name>; et al. <article-title>Integrated Proteogenomic
Characterization of HBV-Related Hepatocellular
Carcinoma</article-title>. <source>Cell</source><year>2019</year>, <volume>179</volume>, <fpage>561</fpage>–<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.052</pub-id>.<pub-id pub-id-type="pmid">31585088</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Nørregaard
Jensen</surname><given-names>O.</given-names></name><article-title>Modification-specific proteomics: characterization of post-translational
modifications by mass spectrometry</article-title>. <source>Curr. Opin
Chem. Biol.</source><year>2004</year>, <volume>8</volume>, <fpage>33</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2003.12.009</pub-id>.<pub-id pub-id-type="pmid">15036154</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Derouiche</surname><given-names>A.</given-names></name>; <name><surname>Cousin</surname><given-names>C.</given-names></name>; <name><surname>Mijakovic</surname><given-names>I.</given-names></name><article-title>Protein phosphorylation from the
perspective of systems biology</article-title>. <source>Curr. Opin Biotechnol</source><year>2012</year>, <volume>23</volume>, <fpage>585</fpage>–<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/j.copbio.2011.11.008</pub-id>.<pub-id pub-id-type="pmid">22119098</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Cerami</surname><given-names>E.</given-names></name>; et al. <article-title>The cBio cancer genomics
portal: an open platform for exploring multidimensional
cancer genomics data</article-title>. <source>Cancer Discov</source><year>2012</year>, <volume>2</volume>, <fpage>401</fpage>–<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id>.<pub-id pub-id-type="pmid">22588877</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Tang</surname><given-names>Z.</given-names></name>; et al. <article-title>GEPIA: a web server
for cancer and normal gene expression profiling
and interactive analyses</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>, <volume>45</volume>, <fpage>W98</fpage>–<lpage>w102</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id>.<pub-id pub-id-type="pmid">28407145</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>F.</given-names></name>; <name><surname>Chandrashekar</surname><given-names>D. S.</given-names></name>; <name><surname>Varambally</surname><given-names>S.</given-names></name>; <name><surname>Creighton</surname><given-names>C. J.</given-names></name><article-title>Proteogenomic characterization of
2002 human cancers
reveals pan-cancer molecular subtypes and associated pathways</article-title>. <source>Nat. Commun.</source><year>2022</year>, <volume>13</volume>, <fpage>2669</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30342-3</pub-id>.<pub-id pub-id-type="pmid">35562349</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Chandrashekar</surname><given-names>D. S.</given-names></name>; et al. <article-title>UALCAN: A Portal for
Facilitating Tumor Subgroup Gene Expression
and Survival Analyses</article-title>. <source>Neoplasia</source><year>2017</year>, <volume>19</volume>, <fpage>649</fpage>–<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1016/j.neo.2017.05.002</pub-id>.<pub-id pub-id-type="pmid">28732212</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18">et al. <article-title>The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue
gene regulation in humans</article-title>. <source>Science</source>
<year>2015</year>, <volume>348</volume>, <fpage>648</fpage>–<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1126/science.1262110</pub-id>.<pub-id pub-id-type="pmid">25954001</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Moore</surname><given-names>H. F.</given-names></name>; et al. <article-title>The Genotype-Tissue
Expression (GTEx) project</article-title>. <source>Nat. Genet.</source><year>2013</year>, <volume>45</volume>, <fpage>580</fpage>–<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2653</pub-id>.<pub-id pub-id-type="pmid">23715323</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Uhlén</surname><given-names>M.</given-names></name>; et al. <article-title>Proteomics. Tissue-based
map of the human proteome</article-title>. <source>Science</source><year>2015</year>, <volume>347</volume>, <fpage>1260419</fpage><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>.<pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Vasaikar</surname><given-names>S. V.</given-names></name>; <name><surname>Straub</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name><article-title>LinkedOmics: analyzing
multi-omics data within and across 32 cancer types</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>, <volume>46</volume>, <fpage>D956</fpage>–<lpage>D963</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1090</pub-id>.<pub-id pub-id-type="pmid">29136207</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Cox</surname><given-names>J.</given-names></name>; <name><surname>Mann</surname><given-names>M.</given-names></name><article-title>MaxQuant enables high peptide identification rates, individualized
p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title>. <source>Nat. Biotechnol.</source><year>2008</year>, <volume>26</volume>, <fpage>1367</fpage>–<lpage>1372</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id>.<pub-id pub-id-type="pmid">19029910</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Cox</surname><given-names>J.</given-names></name>; et al. <article-title>Andromeda: a peptide search engine integrated into the MaxQuant environment</article-title>. <source>J. Proteome Res.</source><year>2011</year>, <volume>10</volume>, <fpage>1794</fpage>–<lpage>1805</lpage>. <pub-id pub-id-type="doi">10.1021/pr101065j</pub-id>.<pub-id pub-id-type="pmid">21254760</pub-id></mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Yu</surname><given-names>S. H.</given-names></name>; <name><surname>Kyriakidou</surname><given-names>P.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>Isobaric Matching between Runs and
Novel PSM-Level Normalization in MaxQuant Strongly Improve Reporter
Ion-Based Quantification</article-title>. <source>J. Proteome Res.</source><year>2020</year>, <volume>19</volume>, <fpage>3945</fpage>–<lpage>3954</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00209</pub-id>.<pub-id pub-id-type="pmid">32892627</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Lundby</surname><given-names>A.</given-names></name>; et al. <article-title>Oncogenic Mutations
Rewire Signaling Pathways by Switching Protein
Recruitment to Phosphotyrosine Sites</article-title>. <source>Cell</source><year>2019</year>, <volume>179</volume>, <fpage>543</fpage>–<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.09.008</pub-id>.<pub-id pub-id-type="pmid">31585087</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Noujaim</surname><given-names>J.</given-names></name>; <name><surname>Payne</surname><given-names>L. S.</given-names></name>; <name><surname>Judson</surname><given-names>I.</given-names></name>; <name><surname>Jones</surname><given-names>R. L.</given-names></name>; <name><surname>Huang</surname><given-names>P. H.</given-names></name><article-title>Phosphoproteomics
in translational research: a sarcoma perspective</article-title>. <source>Ann. Oncol</source><year>2016</year>, <volume>27</volume>, <fpage>787</fpage>–<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdw030</pub-id>.<pub-id pub-id-type="pmid">26802162</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Mylona</surname><given-names>A.</given-names></name>; et al. <article-title>Opposing effects of Elk-1 multisite phosphorylation shape its response
to ERK activation</article-title>. <source>Science</source><year>2016</year>, <volume>354</volume>, <fpage>233</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1126/science.aad1872</pub-id>.<pub-id pub-id-type="pmid">27738173</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
